Press Releases & News
Circle Pharma appoints Evelyn Wang, PhD as its Vice President, Translational Medicine
Evelyn Wang, PhD has joined Circle Pharma as its Vice President of Translational Medicine and will lead Circle’s translational team in its development of macrocycle therapeutics against intractable cancer targets.[...]
Circle Pharma raises $66 Million in Series C Financing
Circle Pharma raises $66 Million in Series C Financing[...]
Circle Pharma appoints Constantine Kreatsoulas, PhD as its Vice President, Research Informatics and Computational Chemistry
Circle Pharma appoints Constantine Kreatsoulas, PhD as its Vice President, Research Informatics and Computational Chemistry.[...]
Circle Pharma Appoints James Aggen, PhD as Its Vice President, Medicinal Chemistry
Circle adds experienced drug hunter Dr. James Aggen to its growing team as Vice President of Medicinal Chemistry.[...]
Circle Pharma Appoints Alan Ashworth, PhD, FRS and Bruce Stillman, PhD, FRS to Its SAB
Renowned scientists Dr. Bruce Stillman and Dr. Alan Ashworth join Nobel laureate Dr. William Kaelin on Circle Pharma's Scientific Advisory Board.[...]
Circle Pharma Appoints Rajinder Singh, PhD as its Chief Science Officer
Circle Pharma Appoints Rajinder Singh, PhD as its Chief Science Officer[...]
Circle Pharma Appoints William G. Kaelin Jr. MD as Chair of Its Scientific Advisory Board
Circle Pharma has appointed 2019 Nobel Laureate William G. Kaelin Jr., MD as its lead science advisor and chair of its SAB.[...]
Circle Pharma raises $45 Million in Series B Financing
Circle Pharma closes $45M series B financing led by The Column Group to support its macrocycle drug development work. [...]
Circle Pharma Congratulates Dr. William G. Kaelin, Jr., MD on Award of Nobel Prize
Circle Pharma congratulates 2019 Nobel laureate Dr. Bill Kaelin. Dr. Kaelin advises Circle on its work to develop cyclin inhibitors for cancer., [...]
Peptide Therapeutics Near the Sweetest Spots
Peptide therapeutics would seem to occupy a sweet spot between small molecules and biologics. Small molecules, which represent the majority of clinical drugs, preferentially bind hydrophobic pockets or cavities, [...]
Circle Pharma’s work with Pfizer yields new macrocyclic peptides
Circle Pharma Inc. said its first collaboration with Pfizer Inc. has led to the identification of a series of bioavailable macrocyclic peptides capable of acting as potent and cell-permeable modulators of CXCR7. [...]
Circle Pharma Announces Publication in Journal of Medicinal Chemistry of Results from Collaboration with Pfizer Inc.
Results from its collaborative work with Pfizer to develop a potent and orally bioavailable macrocycle modulator have been published [...]
Circle Pharma Announces Appointment of David Spellmeyer, PhD, as Chief Scientific Officer
David Spellmeyer, PhD, has been appointed as Circle Pharma's chief scientific officer [...]
Circle Pharma announces expansion of Series A financing and appointment of James C. Lu to its board
An expansion of Series A financing has been completed, with new investors W.I. Harper Group, [...]
Circle Pharma announces Series A financing and appoints Walter H. Moos, Ph.D., to its board
Series A financing round has been announced in which over $4.5M of shares have been issued [...]
Circle Pharma enters into an agreement with Pfizer to build screening library of macrocyclic peptides
Designing and creating a physical screening library of novel macrocyclicpeptides [...]
Circle Pharma Announces Appointment of Co-Founder Prof. Matthew Jacobson to Department Chair
Co-founder Prof. M. Jacobson has been appointed Chair of the UCSF Department of Pharm. Chemistry [...]
Circle Pharma Announces Receipt of Additional Seed Investment, and Relocation to New Laboratory Facility
The seed funding round has been extended with an investment from ShangPharma Investment Group [...]
Starting up and spinning out: The changing nature of partnerships between pharma and academia
In 2005, two chemists decided to work together to develop libraries of cyclic peptides that could be used to treat a range of infectious diseases, autoimmunity and cancer [...]
Full circle: Startup scores big deal with Pfizer — and QB3 is happy
Startup Circle Pharma Inc., a UCSF and UC Santa Cruz spinout devising ways to disrupt a wide variety of diseases from inside cells, will work with Pfizer Inc. on two drug programs [...]
Circle Pharma Announces Receipt of Seed Funding and Initiation of Two Collaborations
Circle Pharma has received seed funding from Pfizer Inc. and QB3’s seed-stage venture fund, Mission Bay Capital, LLC, and has initiated two collaborations with Pfizer [...]